These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36969856)

  • 1. Survival and complications of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with intra-abdominal malignancies: A meta-analysis of randomized controlled trials.
    Jian C; Mou H; Zhang Y; Fan Q; Ou Y
    Front Pharmacol; 2023; 14():1094834. PubMed ID: 36969856
    [No Abstract]   [Full Text] [Related]  

  • 2. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
    Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.
    Li J; Wang AR; Chen XD; Zhang YX; Pan H; Li SQ
    World J Surg Oncol; 2022 Jun; 20(1):200. PubMed ID: 35701802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 5. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials.
    Filis P; Mauri D; Markozannes G; Tolia M; Filis N; Tsilidis K
    ESMO Open; 2022 Oct; 7(5):100586. PubMed ID: 36116421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis.
    Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
    Eur J Surg Oncol; 2019 Mar; 45(3):301-309. PubMed ID: 30786961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
    Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F
    BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical Options for Peritoneal Surface Metastases from Digestive Malignancies-A Comprehensive Review.
    Eftimie MA; Potlog G; Alexandrescu ST
    Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: a systematic review.
    Eveno C; Pocard M
    Pleura Peritoneum; 2016 Dec; 1(4):169-182. PubMed ID: 30911621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness.
    Gurusamy K; Vale CL; Pizzo E; Bhanot R; Davidson BR; Mould T; Mughal M; Saunders M; Aziz O; O'Dwyer S
    BMJ Open; 2020 May; 10(5):e039314. PubMed ID: 32404398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in Ovarian Cancer: An Umbrella Review of Meta-Analyses.
    Souadka A; Essangri H; Majbar MA; Benkabbou A; Boutayeb S; You B; Glehen O; Mohsine R; Bakrin N
    Front Oncol; 2022; 12():809773. PubMed ID: 35615149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence.
    Huang CQ; Min Y; Wang SY; Yang XJ; Liu Y; Xiong B; Yonemura Y; Li Y
    Oncotarget; 2017 Aug; 8(33):55657-55683. PubMed ID: 28903452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: A systematic review and meta-analysis.
    Kim SI; Cho J; Lee EJ; Park S; Park SJ; Seol A; Lee N; Yim GW; Lee M; Lim W; Song G; Chang SJ; Kim JW; Kim HS
    Medicine (Baltimore); 2019 Dec; 98(50):e18355. PubMed ID: 31852138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
    Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
    JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
    Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
    Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.
    Xia Y; Wang H; Zhang J; Wang Y
    Int J Hyperthermia; 2023; 40(1):2165729. PubMed ID: 36775583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis.
    Zhang G; Zhu Y; Liu C; Chao G; Cui R; Zhang Z
    J Ovarian Res; 2019 Apr; 12(1):33. PubMed ID: 30995948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials.
    Granieri S; Bonomi A; Frassini S; Chierici AP; Bruno F; Paleino S; Kusamura S; Germini A; Facciorusso A; Deraco M; Cotsoglou C
    Eur J Surg Oncol; 2021 Nov; 47(11):2757-2767. PubMed ID: 34001385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer with Peritoneal Carcinomatosis: A Systematic Review and Meta-analysis.
    Martins M; Santos-Sousa H; Araújo F; Nogueiro J; Sousa-Pinto B
    Ann Surg Oncol; 2022 Nov; 29(12):7528-7537. PubMed ID: 35930109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ
    Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.